Atrium Therapeutics, Inc. (RNA)
Last updated: 2026-10-21 21:39:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Atrium Therapeutics, Inc. (RNA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.00, with a market capitalization of $130.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.49 to $73.06. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$130.17M | |
$7.97 | |
$73.06 | |
$3.43 | |
$7.98 | |
171.70K | |
265.03K | |
-- | |
$73.06 | |
$7.49 | |
-- | |
-- |
Atrium Therapeutics, Inc. (RNA) After-Hours Stock Price
Atrium Therapeutics, Inc. (RNA) is trading at $8.01 in after-hours trading as of 2026-10-21 19:59:52, up 0.31% ($0.03) from the regular-session close of $7.98.
After-hours trading shows how investors are pricing RNA after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Atrium Therapeutics, Inc. (RNA) 7-Day Stock Price Change
Over the past seven days, Atrium Therapeutics, Inc. (RNA) moved from $8.21 to $8.00, representing a decline of 2.56% ($0.21).
The stock traded between $7.49 and $8.48 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 207.10 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
RNA 52-Week Price Position
Position in Range: 0.8%
RNA is currently trading at $8.00, placing it 0.8% of the way from its 52-week low of $7.49 to its 52-week high of $73.06. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Atrium Therapeutics, Inc. (RNA)?
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Atrium Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 391 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Atrium Therapeutics, Inc. (RNA) Stock on MEXC
Eligible investors can buy real shares of Atrium Therapeutics, Inc. (RNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Atrium Therapeutics, Inc. (RNA) stock price today?
2.Is RNA stock going up or down today?
3.What is RNA pre-market price?
4.What is RNA after-hours price?
5.Is RNA stock trading now?
6.Where does RNA sit relative to its 52-week high and low?
7.What sector is Atrium Therapeutics, Inc. in?
8.What is Atrium Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is RNA valued in terms of P/E ratio and EPS?
10.Does Atrium Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
RNA Stock Calculator
Estimate the value between RNA shares and USD.
RNA Shares to USD
1.00 RNA shares = 8 USD
Calculations are estimates based on the latest available price and are for reference only.


